Back to Search
Start Over
Effects of proangiotensin-12 infused continuously over 14 days in conscious rats.
- Source :
-
European journal of pharmacology [Eur J Pharmacol] 2012 May 15; Vol. 683 (1-3), pp. 186-9. Date of Electronic Publication: 2012 Mar 06. - Publication Year :
- 2012
-
Abstract
- The carboxyl terminal-extended form of angiotensin I, proangotensin-12, was recently identified in rat tissues including the small intestine, cardiac ventricles, and kidneys. Single administration of proangiotensin-12 exerts vasoconstrictor and pressor effects, probably by conversion to angiotensin II; however, there are currently no data available about the subacute effects of proangiotensin-12. In the present study, we examined the effects of prolonged infusion of proangiotensin-12 in conscious rats. Continuous, subcutaneous infusion of 240 pmol/kg/min of proangiotensin-12 gradually elevated blood pressure over 14 days, as did the same dose of angiotensin II. The pressor effects of proangiotensin-12 were abolished by oral administration of losartan, an angiotensin II type 1 receptor blocker, or perindopril, an angiotensin converting enzyme (ACE) inhibitor. Meanwhile, angiotensin II-induced elevation of blood pressure was inhibited by losartan but not by perindopril. Both the plasma aldosterone level and heart weight/body weight ratio were increased by the prolonged infusion of proangiotensin-12, but these increases were attenuated by losartan and perindopril. The present results suggest that proangiotensin-12 infused continuously over 14 days exerts pressor effects accompanied with the elevation of plasma aldosterone and cardiac hypertrophy in an ACE- and angiotensin II type 1 receptor-dependent manner.<br /> (Copyright © 2012 Elsevier B.V. All rights reserved.)
- Subjects :
- Aldosterone blood
Angiotensin II administration & dosage
Angiotensin II adverse effects
Angiotensin II antagonists & inhibitors
Angiotensin II Type 1 Receptor Blockers therapeutic use
Angiotensin-Converting Enzyme Inhibitors therapeutic use
Angiotensinogen administration & dosage
Angiotensinogen antagonists & inhibitors
Animals
Antihypertensive Agents therapeutic use
Cardiomegaly blood
Cardiomegaly pathology
Cardiomegaly prevention & control
Heart drug effects
Hypertension blood
Hypertension pathology
Hypertension prevention & control
Infusions, Subcutaneous
Male
Myocardium pathology
Organ Size drug effects
Peptide Fragments administration & dosage
Peptide Fragments antagonists & inhibitors
Random Allocation
Rats
Rats, Wistar
Time Factors
Vasoconstrictor Agents administration & dosage
Vasoconstrictor Agents antagonists & inhibitors
Weight Gain drug effects
Angiotensinogen adverse effects
Cardiomegaly chemically induced
Hypertension chemically induced
Peptide Fragments adverse effects
Vasoconstrictor Agents adverse effects
Subjects
Details
- Language :
- English
- ISSN :
- 1879-0712
- Volume :
- 683
- Issue :
- 1-3
- Database :
- MEDLINE
- Journal :
- European journal of pharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 22414812
- Full Text :
- https://doi.org/10.1016/j.ejphar.2012.02.037